The therapeutic benefit of azathioprine over a 5-years period in a single child wrongly classified as pediatric MS, but with a clinical phenotype of relapsing MOG-IgG associated disorder, has been recently published (95). This evidence concerns the gene MOG and myeloid sarcoma.